Searchable abstracts of presentations at key conferences in endocrinology

ea0081d1.1 | PRRT or targeted molecular therapies as preferred line of treatment | ECE2022

For: PRRT or targeted molecular therapies as preferred line of treatment

de Herder Wouter W

Purpose: Bronchopulmonary (BP) and gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are slow-growing tumors, which frequently express somatostatin receptors on their cell membranes. These receptors are targets for therapy with 177Lutetium-labeled somatostatin analogues.Experimental Design: Patients receive four treatments of 177Lu-DOTATATE at a dose of 7.4 GBq every 8 weeksResults: An objective resp...

ea0016me14 | (1) | ECE2008

Management of GI-NET

de Herder Wouter W

According to the WHO classification system the majority of endocrine tumours of the gastrointestinal tract (GI-NETs) are considered as being well differentiated benign or malignant tumours. Almost all GI-NETs are derived from enterochromaffin or Kulchitsky cells that can synthesize, store and secrete serotonin. The majority of these tumours are non-functioning and their presentation is non-specific. Functioning tumours, may exhibit protean clinical presentation, depending on t...

ea0020p551 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

The low-dose ACTH stimulation test in the assessment of outcome of pituitary surgery for Cushing's disease

Alwani Rehmat A , De Herder Wouter W , De Jong Frank H , Van der Lely Aart-Jan , Feelders Richard A

Objective: To evaluate the results of the early postoperative low-dose (1 μg) ACTH (adrenocorticotropin) stimulation test in patients with Cushing’s disease (CD) in order to predict long-term outcome of transsphenoidal surgery.Methods: We reviewed the serum cortisol response to 1 μg synthetic ACTH (1–24) in the second week after pituitary surgery in 40 patients with Cushing’s disease. Median follow-up was 48.5 months (range 6&#15...

ea0056p129 | Endocrine tumours and neoplasia | ECE2018

The effect of temozolomide on pancreatic neuroendocrine tumours and role of MGMT and MMR system in temozolomide resistance

Blazevic Anela , Dogan-Oruc Fadime , Dedeci Mehtap , van Koetsveld Peter M. , Feelders Richard A. , de Herder Wouter W. , Hofland Leo J.

Background: Temozolomide (TMZ) has been suggested as a treatment option for patients with pancreatic neuroendocrine tumours (PNETs). The tumour response to TMZ has been linked to expression levels of O6-methylguanine-DNA methyltransferase (MGMT) and components of the mismatch repair (MMR) system. However, there is no in vitro data on TMZ sensitivity and the expression of MGMT and MMR components in PNETs. Moreover, the effect of TMZ exposure on chemosensitivity and exp...

ea0099p502 | Endocrine-Related Cancer | ECE2024

Ovarian neuroendocrine tumor metastases can induce estrogen production in postmenopausal patients

Mulders Merijn , van Velthuysen M F , Roes Eva Maria , Hofland Leo , de Herder Wouter W , Hofland Hans

Background: Neuroendocrine tumors (NET) are malignant neoplasms that can be associated with specific hormonal syndromes. We describe a novel syndrome of postmenopausal vaginal bleeding and ovarian estradiol overproduction due to ovarian NET localizations.Methods: A clinical workup was performed for 2 index patients with ovarian metastases of small bowel neuroendocrine tumors and symptoms of postmenopausal vaginal bleeding. Ovarian tissue was collected af...

ea0081p646 | Endocrine-Related Cancer | ECE2022

Methodology of the SORENTO clinical trial: assessing the efficacy and safety of high exposure octreotide subcutaneous depot in patients with GEP-NETs

Ferone Diego , Capdevilla Jaume , Ang Chan Jennifer , de Herder Wouter W , Halperin Daniel , Mailman Josh , Singh Simron , Dorkhan Mozhgan , Hellstrom Lisa , Svedberg Agneta , Tiberg Fredrik

Background: Somatostatin receptor ligands (SRLs) are first-line standard-of-care therapies for gastroenteropancreatic neuroendocrine tumours (GEP-NETs), showing efficacy in tumour and symptom control with an established safety profile. However, disease progression may occur despite standard-dose SRL treatment, requiring more aggressive and toxic treatments. Retrospective/non-randomized data suggest higher-dose SRLs may benefit patients with GEP-NETs who do not respond to stand...

ea0037ep94 | Adrenal cortex | ECE2015

Combined effects of sirolimus and mitotane in the inhibition of growth in human adrenocortical carcinoma cells

De Martino Maria Cristina , van Koetsveld Peter M , Feeldes Richard A , Lamberts Steven W J , de Herder Wouter W , Colao Annamaria , Pivonello Rosario , Hofland Leo J

Adrenocortical cancer (ACC) is a rare cancer with poor prognosis and scant treatment options. Mitotane alone, or in combination with cytotoxic chemotherapy, represents the referral current treatment for patients with unresectable ACC. Recent studies have shown that mTOR inhibitors suppress growth of ACC cells. This study aimed at evaluating the effects of mitotane in combination with mTOR inhibitors. In H295 and SW13 cells we tested the effects of a 6 day treatment with increa...

ea0070aep626 | Pituitary and Neuroendocrinology | ECE2020

Surgical and survival outcomes of early peptide receptor radionuclide therapy for downstaging locally advanced or oligometastatic pancreatic neuroendocrine neoplasms

Minczeles Noémie , van Eijck CHJ , van Gils MJ , van Velthuysen MF , Nieveen van Dijkum EJM , Feelders Richard , de Herder Wouter W , Brabander* T , Hofland* Hans

Introduction: Pancreatic neuroendocrine neoplasm (pNEN) patients often present with locally advanced or metastatic disease. The objective response rate of peptide receptor radionuclide therapy (PRRT) in pNENs is 55%. Therefore, PRRT may be a possibility for patients who are not eligible for upfront curative surgery.Aims: To assess the potency of PRRT to render locally advanced or oligometastatic pNENs resectable and to evaluate the effect of surgery afte...

ea0020p52 | Adrenal | ECE2009

Expression of mTOR pathway in human adrenocortical carcinomas and in vitro effects of mTOR inhibitors in human adrenocortical cell lines

De Martino Maria Cristina , van Koetsveld Peter , Sprij-Mooij Diana , Feelders Richard A , Lamberts Steven W J , de Herder Wouter W , Colao Annamaria , Pivonello Rosario , Hofland Leo J

Background: Adrenocortical carcinoma (ACC) is an uncommon malignancy with a still scantily understood pathogenesis and generally poor prognosis. Surgery, performed at early stages, offers the best chance for cure, but unfortunately, it is often noncurative. Medical treatment produced disappointing responses. mTOR inhibitors, such as sirolimus (S) and temsirolimus (T), are promising antineoplastic drugs in several types of carcinomas.Methods: To evaluate ...

ea0016p395 | Neuroendocrinology | ECE2008

Dopamine receptor expression and dopamine agonist effectiveness in corticotroph pituitary tumors: comparison with clinical, biochemical radiological and pathological features of patients with Cushing's disease

Pivonello Rosario , de Herder Wouter W , Ferone Diego , Kros Johan M , De Caro Maria Laura Del Basso , Lombardi Gaetano , Colao Annamaria , Hofland Leo J , Lamberts Steven WJ

Dopamine receptors (DR) are expressed in the majority of corticotroph pituitary tumors and the dopamine agonist cabergoline is effective in controlling cortisol hypersecretion in around 50% of patients with Cushing’s disease (CD). In order to characterize the tumors expressing D2 receptors and the profile of patients which might respond to the treatment with D2 agonists, the current study has the aim to correlate D2 receptor expression and...